SCHEMBL6743161

SCHEMBL6743161

CCCn1[c]cc(C(F)(F)F)n1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.31
ADORA2A P29274 1/20 0.30
ADORA2B P29275 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL535436 0.85
SCHEMBL192417 0.74 KDM4E (0.31) LMNA
SCHEMBL6741096 0.72
SCHEMBL16910904 0.71 ADORA2A (0.32) ADORA2AADORA2B
SCHEMBL3675830 0.71
SCHEMBL217424 0.67
SCHEMBL535386 0.67
SCHEMBL535541 0.65 IDH1 (0.30)
SCHEMBL15417666 0.64 LMNA (0.43) LMNA
SCHEMBL538163 0.62 LMNA (0.44) LMNAADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103180316-A Compounds that modulate intracellular calcium CALCIMEDICA INC 2013-06-26 CN disclosed
US-20040023805-A1 Substituted phenyluracils ANDREE ROLAND (DE) 2004-02-05 US disclosed
US-6649760-B2 Herbicides BAYER AKTIENGESELLSCHAFT (DE) 2003-11-18 US disclosed
CN-1420873-A Substituted phenyluracils BAYER AG (DE) 2003-05-28 CN disclosed
EP-1272478-A1 SUBSTITUTED PHENYLURACILS Bayer Aktiengesellschaft (DE) 2003-01-08 EP disclosed
US-20020173425-A1 Substituted phenyluracils BAYER AKTIENGESELLSCHAFT (DE) 2002-11-21 US disclosed
WO-2001077084-A1 SUBSTITUTED PHENYLURACILS BAYER CROPSCIENCE AG (DE) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020173425-A1 Substituted phenyluracils DPYD, POP1, G6PD LMNA 4406/4885ADORA2A 2147/4885ADORA2B 2626/4885
US-20040023805-A1 Substituted phenyluracils DPYD, POP1, G6PD LMNA 4406/4885ADORA2A 2147/4885ADORA2B 2626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.